Репродукция и энергетический баланс: интегративная роль пролактина

Физиологические механизмы, координирующие репродукцию, тесно связаны с регуляцией энергетического баланса. За последние годы накопилось множество данных, свидетельствующих о том, что помимо влияния на молочные железы, пролактин участвует в регуляции метаболизма. Гиперпролактинемия ассоциирована с ожирением, лечение агонистами дофамина способствует снижению массы тела. В данном обзоре обсуждается роль пролактина в интеграции метаболического контроля и репродуктивной функции, вклад гормона в развитие ожирения, а также влияние терапии каберголином на массу тела и другие факторы риска сердечно-сосудистых заболеваний.

пролактин, репродукция, энергетический баланс, ожирение, каберголин

1. Астафьева Л.И. Клинико-морфологические особенности и результаты медикаментозного и хирургического методов лечения пролактин-секретирующих макроаденом гипофиза. Автореф. дис. … д.м.н. М., 2012.

2. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М.: «Триада», 2004: 304 с.

3. Дзеранова Л.К., Мокрышева Н.Г., Бармина И.И. и соавт. Метаболические эффекты пролактина. Вестник репродуктивного здоровья; 2008 (4): 29-32.

4. Курляндская Р.М., Романцова Т.И. Влияние гиперпролактинемии на основные показатели жирового обмена. Леч. врач. 2004; 1: 73-75.

5. Мельниченко Г.А., Марова Е.И., Дзеранова Л.К., Вакс В.В. Гиперпролактинемия у женщин и мужчин. М., 2007: 45с.

6. Осипова А.А., Сметник В.П. Избыточная масса тела и абдоминальный тип ожирения у пациенток с опухолевой и неопухолевой формами гиперпролактинемии; влияние терапии парлодолом, норпролаком и достинексом. Проблемы репродукции. 2002; 1: 12-17.

7. Черноголов В.А. Особенности диагностики и лечебной тактики при микроаденомах гипофиза, сопровождающихся пограничной гиперпролактинемией. Автореф. дис. … к. м. н. М., 1999: 23.

8. Athanasoulia A.P., Sievers C., M. Uhr et al. The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas. Pituitary. 2013; doi. 10.1007/s11102-013-0496-y.

9. Auffret J., Viengchareun S., Carré N. et al. Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity. FASEB J. 2012; 26(9): 3728-3737. doi: 10.1096/fj.12-204958.

10. Augustine R., Ladyman S.R., Grattan D.R. From feeding one to feeding many: hormone-induced changes in bodyweight homeostasis during pregnancy. J Physiol. 2008: 387-397.

11. Auriemma R.S. Granieri L. Galdiero M. et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinol. 2013; doi:10.1159/000357810

12. Begg D.P., Woods S.C. The endocrinology of food intake. Nat Rev Endocrinol. 2013; 9(10): 584-597. doi: 10.1038/nrendo.`

13. Ben-Jonathan N., Hugo E.R., Brandebourg T.D., LaPensee C.R. Focus on prolactin as a metabolic hormone. Trends in endocrinology and metabolism. 2006; 17(3): 110-116.

14. Ben-Jonathan N., LaPensee C.R., LaPensee E.W. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008; 29: 1-41. doi: 10.1210/er.2007-0017.

15. Bernabeu I., Casanueva F. F. Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment? Endocrine. 2013; 44 (2): 273-274

16. Berthoud H-R. Metabolic and hedonic drives in the neural control of appetite: Who’s the boss? Curr Opin Neurobiol. 2011; 21(6): 888-896.

17. Borcherding D.C., Hugo E.R., Idelman G. et al. Dopamine receptors in human adipocytes: expression and functions. PLoS One. 2011; 6(9). doi: 10.1371/journal.pone.0025537.

18. Bouckenooghe T., Sisino G., Aurientis S. et al. Adipose tissue macrophages (ATM) of obese patients are releasing increased levels of prolactin during an inflammatory challenge: A role for prolactin in diabesity? Biochim Biophys Acta. 2013; doi: 10.1016/j.bbadis.

19. Brunton P.J., Russel J.A. The expectant brain: adapting for motherhood. Nature Rev Neurosci. 2008; 9: 11-25.

20. Carre N., Binart N. Prolactin and adipose tissue. Biochimie. 2014; 97: 16-21. doi: 10.1016/j.biochi.2013.09.023.

21. Chen P., Smith M.S. Regulation of hypothalamic neuropeptide Y messenger ribonucleic acid expression during lactation: role of prolactin. Endocrin. 2004; 145(2): 823-829.

22. Ciresi A., Amato M.C., Guarnotta V. et al. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol. 2013; 79 (6): 845-852.

23. Devi Y., Halperin Y. Reproductive actions of prolactin mediated through short and long receptor isoforms. Mol Cell Endocrinol. 2014; 382(1): 400-410. doi: 10.1016/j

24. dos Santos Silva C.M., Barbosa F.R., Lima G.A. et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011; 19: 800-805.

25. Elias C.F., Purohit D. Leptin signaling and circuits in puberty and fertility. Cell Mol Life Sci. 2013; 70: 841-862.

26. Frisch RE, Revelle R. Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science. 1970; 169(943): 397-399.

27. Fu L-Y., van den pon A.N. Kisspeptin directly excites anorexigenic proopiomelanocortin neurons but inhibits orexigenic neuropeptide Y cells by an indirect synaptic mechanism. J Neurosci. 2010; 28(30): 10205-10219.

28. Garcia-Garcia R.M. Integrative control of energy balance and reproduction in females. Int Schol Res Net. 2012: 51-64.

29. Gibson C.D., Karmally W., McMahon D.J. et al. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab. 2012; 14(4): 335-40. doi: 10.1111/j.1463-1326.2011.01534.x.

30. Grattan D.R., Kokay I.C. Prolactin: a pleiotropic neuroendocrine hormone. J Neuroendocrinol. 2008; 20: 752-763.

31. Haring R., Friedrich N., Volzke H. et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J., 2012; doi: 10.1093/eurheartj/ehs233

32. Hirschberg L.A. Sex hormones, appetite and eating behaviour in women. Maturitas. 2012; 71: 248-256.

33. https://www.rosminzdrav.ru/docs/mzsr/standards/projects/518

34. Hussain S.S., Bloom S.R. The regulation of food intake by the gut-brain axis: implications for obesity. Int J Obes (Lond). 2012; doi: 10.1038/ijo.2012.

35. Inancli S.S., Usluogullari A., Ustu Y. et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine. 2013; 44(1): 193-1999. doi: 10.1007/s12020-012-9857-y.

36. Kaiser U.B. Hyperprolactinemia and infertility: new insights. JCI. 2012; 22:3467-3468.

37. Kenny P. J. Reward mechanisms in obesity: new insights and future directions. Neuron. 2011; 69 (4): 664-679.

38. Kopelman P.G. Physiopathology of prolactin secretion in obesity. Int J Obes Relat Metab Disord. 2000; 24 (Suppl 2): 104-108.

39. Kok P., Roelfsema F., Frolich M. et al. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab. 2004; 89(9): 4445-4449. doi 10.1210/jc.2003-032184.

40. Korner J., Lo J., Freda P. U. Wardlow S.L. Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res. 2003; 11(2): 311-312.

41. Ladyman S.R. Augustine R., Grattan D.R Hormone interactions regulating energy balance during pregnancy. J Neuroendocrinol. 2010; 22: 805-817.

42. Mauvais-Jarvis F., Clegg D.J., Hevener A.L. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013; 34(3): 309-338.

43. Melmed S., Casanueva F.F., Hoffman A.R. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(2): 273-88. doi: 10.1210/jc.2010-1692.

44. Mircea C.N., Lujan M.E., Pierson R.A. Metabolic fuel and clinical implications for femal reproduction. Gynaecology; 2007; 28: 887-902.

45. Norgan N.G. The beneficial effects of body fat and adipose tissue in human. Int J Obes.1997; 21: 738-746.

46. Orbetsova M., Kamenov Z., Orbetzova V. Is there a «metabolic syndrome» in prolactinomas? Programm and Abstracts of the 10-th Meeting of the Europ Neuroendocrinol Assoc. 2002: p.75.

47. Pereira-Lima J.F.S., Leães C.G.S., Neto F.M.F. et al. Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia. Res J Endocrin Metab. 2013; doi.10.7243/2053-3640-1-2

48. Reuwer A.Q., van Eijk M., Houttuijn-Bloemendaal F.M. et al. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J Endocrinol. 2011; 208:107-117.

49. Roa J. Role of GnRH neurons and their neuronal afferents as key integrators between food intake regulatory signals and the control of reproduction. Int J Endocrinol. 2013.doi 10.1155/2013/518046

50. Roelfsema F., Piji H., Keenan D.M., Veldhuis J.D. Prolactin secretion in healthy adults is determined by gender, age and body mass index. PloS One. 2012; 7(2): e31305. doi:10.1371/journal.pone.0031305

51. Schmid C., Goede D.L., Hauser R.S., Brändle M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006; 136: 254-2588.

52. Seger J.C., Horn D.B., Westman E.C., et al. American Society of Bariatric Physicians Obesity Algorithm: Adult Adiposity Evaluation and Treatment. 2013. www.obesityalgorithm.org.

53. Serri O,, Li L., Mamputu J.C. et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006; 64(4): 366-370.

54. Smith M.S., True C., Grove K.L. The neuroendocrine basis of lactation-induced supresssion of GnRH: role of kisspeptin and leptin. Brain Res.2010; 1364: 139-152.

55. Tessier D.R., Ferraro Z.M., Gruslin A. Role leptin in pregnancy: consequences of maternal obesity. Placenta.2013; 34(3): 205-211.

56. Viengchareun S., Servel N., Fève B. et al. Prolactin receptor signaling is essential for perinatal brown adipocyte function: a role for insulin-like growth factor-2. PLoS One. 2008; 3(2):e1535. doi: 10.1371/journal.pone.0001535.

57. Volkow N.D., Wang G.J., Baler R.D. Reward, dopamine and the control of food intake: implication for obesity. Trends Cogn Sci. 2011; 15(1): 37-46.

58. Wang G.J., Volkow N.D., Thanos P.K. et al. Imaging of brain dopamine pathways: implications for understanding obesity. J Addict Med. 2009; 3(1): 8-18.

59. Woodside B., Budin R., Wellman M.K., Abizaid A. Many mouths to feed: the control of food intake during lactation. Front Neuroendocrinol. 2012; 33(3): 301-314.

60. Zafon C., Simo R. The current obesity epidemic: unravelling the evolutionary legasy of adipose tissue. Obes J. 2011; 3: 98-106.

61. Zinger M., McFarland M., Ben-Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue explants. J Clin Endocrinol Metab. 2003; 88: 689-696.